Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Ingredion Incorporated heads into its November 3 earnings report with short sellers in full retreat, options traders less defensive than they have been in months, and analysts still nudging targets lower.
The most striking development this week is the scale of short covering. Short interest has dropped 21% over the past week, falling to 5.9% of the free float. That unwind took the position from a recent peak of roughly 10.3 million equivalent-exposure shares on October 1 back to 3.75 million. The ORTEX short score tells the same story: it collapsed from 67.4 on October 1 to 48.4 by October 12, erasing what had briefly looked like a meaningful bearish build. With the borrow cost now running at just 0.39%, down 23% on the week, and availability sitting at a very loose 1,186%, there is nothing in the lending market to suggest short sellers are under pressure from a supply squeeze. This was a deliberate covering move, not a forced one.
Options positioning reinforces the shift in sentiment. Put demand has eased considerably: the put/call ratio is at 1.04, roughly 1.65 standard deviations below its 20-day average of 1.22. That marks the lowest defensive reading in months. Through late September the ratio spent two weeks above 1.35, close to the 52-week high of 1.37, so the rotation away from puts has been sharp. The stock itself has been largely unmoved, adding just 0.5% on the week to close at $97.26, but that follows a 3.2% decline over the prior month. Peer performance was mixed: FLO gained 4% on the week while MKC slipped 1.7%, leaving Ingredion in the middle of the pack.
The Street remains cautious but not bearish. Two analyst actions this week: Barclays, on October 14, trimmed its target to $115 from $118 while holding an Equal-Weight rating, and UBS cut to $104 from $108 on October 5, also keeping Neutral. Both moves continue a pattern of steady, modest target reductions from the sidelines rather than outright downgrades. The mean target across the coverage universe is $120, implying roughly 23% upside from the current price, but that gap has been narrowing with each cut. Benchmark initiated coverage in March with a Buy and a $130 target, and Oppenheimer downgraded to Perform in June, so the distribution of views spans from cautious neutrality to modest optimism. Factor scores add texture: Ingredion ranks in just the 25th percentile on short-score positioning and the 8th percentile on days-to-cover, neither of which is alarming at current interest levels. The EV/EBIT rank at the 87th percentile suggests the stock is genuinely cheap relative to the universe, with the PE multiple running at 8.8x and EV/EBITDA at 5.8x.
One data point worth noting from the Wikimedia Foundation's Wikipedia pageview series: retail attention has climbed to a z-score of 2.3 against Ingredion's own 90-day history, as of September 27. This dataset has not been measured to lead the company's financial figures, so it should be read as a gauge of interest rather than a signal about the November print.
On the ownership side, the institutional picture is conventional. BlackRock holds 10.4% and added 184,000 shares as of the September quarter-end. Dimensional Fund Advisors, at 5.3%, added 242,000 shares over the same period. American Century made the largest disclosed move, adding nearly 992,000 shares to reach 2% of the company. First Trust Portfolios, which had been a 13G filer at 6.3%, cut that stake to 3.5% by July. No Schedule 13D activist is on the register.
The only open-market insider trade in the past 90 days was a director sale of 1,662 shares in August at $102.31, a modest transaction with no 10b5-1 plan attached. Given that the stock has since fallen below that sale price to $97.26, the next question is whether insiders add before the November 3 earnings date or whether the pattern of compensation-linked grants remains the dominant form of activity going into the print.
See the live data behind this article on ORTEX.
Open INGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
